Effect of relapses on development of residual deficit in multiple sclerosis.
about
Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotropic hormoneInterferon beta for secondary progressive multiple sclerosisMultidisciplinary rehabilitation for adults with multiple sclerosisFunctional and Structural Brain Plasticity Enhanced by Motor and Cognitive Rehabilitation in Multiple SclerosisThe topographical model of multiple sclerosis: A dynamic visualization of disease courseRisk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple SclerosisEFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapsesProgressive multiple sclerosis: from pathogenic mechanisms to treatment.Outcome Measures in Clinical Trials for Multiple Sclerosis.Management of acute exacerbations in multiple sclerosis.Temporal relationship between environmental influenza A and Epstein-Barr viral infections and high multiple sclerosis relapse occurrence.Impact of multiple sclerosis relapses on progression diminishes with timeEvidence for a two-stage disability progression in multiple sclerosisReduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis : Analysis of Economic Data from the CLARITY Study.Risk stratification and mitigation multiple sclerosis.Multiple sclerosis trial designs for the 21st century: building on recent lessons.Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study.ACTH gel in the treatment of multiple sclerosis exacerbation: a case study.The multiple sclerosis relapse experience: patient-reported outcomes from the North American Research Committee on Multiple Sclerosis (NARCOMS) RegistryRelapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study.Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring.A predictive model for corticosteroid response in individual patients with MS relapsesA tool to measure the attributes of receiving IV therapy in a home versus hospital setting: the Multiple Sclerosis Relapse Management Scale (MSRMS)Multiple sclerosis: diagnosis and the management of acute relapsesThe Lived Experience of Multiple Sclerosis Relapse: How Adults with Multiple Sclerosis Processed Their Relapse Experience and Evaluated Their Need for Postrelapse CareA Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple SclerosisGlatiramer acetate for the treatment of multiple sclerosis.Quantification of optic nerve head topography in optic neuritis: a pilot study.Clinical characteristics of progressive relapsing multiple sclerosis.Response to Therapeutic Plasma Exchange as a Rescue Treatment in Clinically Isolated Syndromes and Acute Worsening of Multiple Sclerosis: A Retrospective Analysis of 90 Patients.Escalating immunotherapy of multiple sclerosis--new aspects and practical application.Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis.ACS chemical neuroscience molecule spotlight on gilenya (fingolimod; FTY720)Vitamin D Status Does Not Affect Disability Progression of Patients with Multiple Sclerosis over Three Year Follow-Up.Combination therapy in multiple sclerosis.Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.African ancestry is a predictor factor to secondary progression in clinical course of multiple sclerosis.Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis.Treatment of acute relapses in multiple sclerosis.Assessment of definitions of sustained disease progression in relapsing-remitting multiple sclerosis.
P2860
Q21558407-9F20965C-4F9E-4F67-A0B1-C6A21EA76734Q24203879-7A545C66-CABE-4AC6-B1D5-2B5FCAA0A49BQ24244018-1EED6F49-0B84-4E0E-AC5B-982EE9D5EE34Q26824972-623E2B98-BC39-4F7F-87B4-9C528F24ABB3Q27312133-311819A0-21FA-4960-8AEF-BA3B18B87AE9Q28087414-8177B770-F843-466E-A914-1EB377278791Q28284851-5B3DF284-F2A5-4C7C-B3AC-B3524F36DD79Q31139925-16CE7D1B-B718-49F2-AA5B-3D328E2110B1Q31160866-DD77CC5C-8DA4-4E67-B0F0-35C54B2DD168Q33670934-A76BA852-50D7-4A77-A2AE-316D46A220B2Q33787783-D142617C-5F6C-4CAA-92C8-F18097272439Q33898204-3700D26B-0836-4318-860C-2A2D6BD2FEA8Q33944184-4AE0DCA4-991E-4219-A275-55E0546F465BQ34053766-891C8F67-866C-44A3-988F-3B4E57DB51EAQ34155446-3C42E903-F53C-4C75-895C-CCDA50E75715Q34463581-35F06C18-B3F3-4127-8E3A-161E8D7F2F36Q34483022-AE4699C9-1B6D-47E2-95E7-03B7603B7B36Q34969795-1C6A9F3A-3445-4768-BF63-7FA1C0E19ED0Q34982119-F115F595-C9A0-4E4F-A0B3-55B69CA2FC21Q35091777-F735ABCF-223C-4F92-A37A-4391827BAEABQ35093103-2784C229-F52A-403A-A59A-992F90F59E33Q35192482-5454E09F-0E1F-4498-803D-7FA73B506AB6Q35305266-F19114A8-CE85-4524-BB8B-7C5531E78FA7Q35521828-208E4A33-3D20-44A5-9C90-84004D7CB8EAQ35649734-4B63076E-347E-4194-ACB5-0343FCEB5B38Q35651621-B6996EFD-C7C9-4139-AA12-0B2511867355Q35753417-EEC249FD-1495-4EF0-883A-B62CE2E9DC15Q35762430-8BBF8079-2876-4D23-A1B3-004A794C39AAQ35870214-F25C5C19-DAC2-4869-8262-17C33B1796D7Q35921568-76EF0D2A-2511-4C04-ABC7-FADDD7F57C6BQ35981192-6C1EACEE-5B71-4458-A20D-05A9F77BC1ECQ36005655-1A0667AB-E66E-4BB3-81DF-040DF0E6EC14Q36015393-6C1D77CE-EC77-44D1-A937-83D93A655C24Q36045080-389645D2-DFDE-4A86-9315-E13FF63D43EBQ36113050-2D2EE7A0-596C-4E63-B710-06F382A24DFAQ36223650-EA6F5340-2CD0-49B3-BD60-E070B321D636Q36440208-695A7F4F-DDA0-4279-A705-1DC9C990FC92Q36538190-1E4F992E-F9EF-4619-8C82-A3130F4AB518Q36568671-705E541F-00C2-4758-AE9B-1D946851B9D1Q36716747-B5072BA0-459C-4D5D-B0E8-48107BF70531
P2860
Effect of relapses on development of residual deficit in multiple sclerosis.
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Effect of relapses on development of residual deficit in multiple sclerosis.
@ast
Effect of relapses on development of residual deficit in multiple sclerosis.
@en
Effect of relapses on development of residual deficit in multiple sclerosis.
@nl
type
label
Effect of relapses on development of residual deficit in multiple sclerosis.
@ast
Effect of relapses on development of residual deficit in multiple sclerosis.
@en
Effect of relapses on development of residual deficit in multiple sclerosis.
@nl
prefLabel
Effect of relapses on development of residual deficit in multiple sclerosis.
@ast
Effect of relapses on development of residual deficit in multiple sclerosis.
@en
Effect of relapses on development of residual deficit in multiple sclerosis.
@nl
P2093
P1433
P1476
Effect of relapses on development of residual deficit in multiple sclerosis.
@en
P2093
Fred D Lublin
Gary Cutter
Monika Baier
P304
P356
10.1212/01.WNL.0000096175.39831.21
P407
P577
2003-12-01T00:00:00Z